A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

NCT00001053 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV p17/p24:Ty-VLP
BIOLOGICAL: Aluminum hydroxide

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)